N
Neurelis
Biotech & Life Sciences · San Diego, United States · Founded 2007
Specialty pharmaceutical firm that licenses, develops, and commercializes product candidates for epilepsy and the cns market MoreLess
Neurelis, Inc. is a neuroscience-based pharmaceutical company focused on delivering innovative therapies designed to address unmet medical needs. The company operates in the pharmaceutical and biotechnology market, serving patients and healthcare professionals (HCPs) with a range of proprietary technologies aimed at enhancing drug delivery and stabilization. Neurelis' business model revolves around the development and commercialization of novel therapeutic solutions, leveraging its proprietary non-invasive drug delivery technologies to improve clinical outcomes and patient care. The company generates revenue through the sale of its pharmaceutical products and through partnerships and collaborations with other entities in the healthcare sector. Neurelis is committed to advancing its pipeline of investigational product candidates, which are at various stages of development, to bring new and effective treatments to market.
Keywords: neuroscience, pharmaceutical, innovative therapies, drug delivery, patient care, proprietary technologies, biotechnology, healthcare professionals, clinical outcomes, investigational products.
Company overview
Neurelis company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2007
- Headquarters
- San Diego, United States
- Employees
- 187
- Open positions
- 8
- Dealroom signal
- 72.7
- Investment activity
- 1 companies · latest Dec 2018
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
Neurelis funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Aug 2021 | $150M | — | OrbiMed | — |
| SERIES DOther financing | Mar 2021 | $114M | $456M | LYZZ Capital · Philos & Partners · Decheng Capital · Cormorant Asset Management | — |
| SERIES COther financing | Oct 2020 | — | — | Undisclosed | — |
| LATE VCOther financing | Nov 2018 | $41M | $162M | Undisclosed | — |
| SERIES BOther financing | Jan 2017 | — | — | LYZZ Capital · HBM Healthcare Investments | — |
| SERIES AOther financing | Feb 2016 | LYZZ Capital | — | ||
| SEEDOther financing | Jul 2015 | Undisclosed | — | ||
| ACQUISITIONOther financing | Jun 2013 | Biotie Therapies | — | ||
| DEBTDebt | Oct 2011 | Undisclosed | — | ||
| DEBTDebt | Feb 2010 | Undisclosed | — |
Growth signals
Neurelis website traffic
Latest recorded traffic for Neurelis is 6.9K monthly website visits, up 53.3% over the last three months. Neurelis's team grew 6.9% over the past year.
Hiring
Open positions at Neurelis
Current openings linked to this company in Dealroom.
Comparisons
Neurelis compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Neurelis investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Neurelis's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Neurelis has talent and traffic
team presence
In the news
Latest news about Neurelis
Recent press, funding announcements, and product moves mentioning Neurelis — open to read from the original sources.
Market sentiment
What the market is saying about Neurelis
An AI-synthesized read of the highest-engagement posts about Neurelis on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neurelis’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.